Automatic implantable cardioverter-defibrillator: Patient survival, battery longevity and shock delivery analysis

The automatic implantable cardioverter-defibrillator (AICD) has been shown to reduce the mortality rate of patients with malignant ventricular tachyarrhythmias. This report describes experience with implantation of 36 automatic implantable cardioverter-defibrillators (AId-B and AID-BR models) in 22...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 1987-06, Vol.9 (6), p.1349-1356
Hauptverfasser: Gabry, Mark D., Brodman, Richard, Johnston, Debra, Frame, Rosemary, Kim, Soo G., Waspe, Lawrence E., Fisher, John D., Furman, Seymour
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1356
container_issue 6
container_start_page 1349
container_title Journal of the American College of Cardiology
container_volume 9
creator Gabry, Mark D.
Brodman, Richard
Johnston, Debra
Frame, Rosemary
Kim, Soo G.
Waspe, Lawrence E.
Fisher, John D.
Furman, Seymour
description The automatic implantable cardioverter-defibrillator (AICD) has been shown to reduce the mortality rate of patients with malignant ventricular tachyarrhythmias. This report describes experience with implantation of 36 automatic implantable cardioverter-defibrillators (AId-B and AID-BR models) in 22 persons over a 44 month patient follow-up period (mean 19.6 months). There were five deaths: two patients died suddenly 22 and 29 months, respectively, after their second implant, one died of congestive heart failure, one died of respiratory failure and one died of catheter sepsis. Although 11 (50%) of the 22 patients never received a countershock for a ventricular tachyarrhythmia and are still alive, the other 11 received one or more spontaneous countershocks. Nine patients (41%) experienced spurious shocks during the follow-up period. Assuming that the first shock for presumed ventricular tachyarrhythmia prevented death, the hypothetical cumulative survival of patients at 42 months would have been 34 ± 14.1% in the absence of an automatic implantable cardioverter defibrillator rather than the actual survival rate of 59 ± 16.8%. The cumulative device survival of the 36 AID-B units was 92 ± 5.62% at 15 months but diminished to 37 ± 14.4% by 20 months. No unit lasted longer than 22 months. There were 12 battery depletions. The number of shocks emitted did not influence unit longevity. The manufacturer's elective replacement indicator is of uncertain validity. Six units remained active 7 to 17 months after surpassing their replacement indicator. The automatic implantable cardioverter-defibrillator prolongs the life of many patients with otherwise intractable arrhythmias. Problems remain with this early generation device including the imprecision of its arrhythmia detection system resulting in false-positive discharges, the limited longevity of its battery, lack of programmability and an inadequate device follow-up system.
doi_str_mv 10.1016/S0735-1097(87)80477-1
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77543450</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0735109787804771</els_id><sourcerecordid>77543450</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-70ceb85972d4abfeb04b4b4bad07c9e13157e0d047ace68e06a702142f8fe9a13</originalsourceid><addsrcrecordid>eNqFkFFrFDEQx4Mo9ax-hEIeRBTcmmw2l2xfpBSthYKC-hxmk1mNZnevSXbhvr1Z77jXkkAe5peZ-f8IueDskjO-_fCdKSErzlr1Vqt3mjVKVfwJ2XApdSVkq56SzQl5Tl6k9IcxttW8PSNnQupG1WJDHq7nPA2QvaV-2AUYM3QBqYXo_LRgzBgrh73vog8B8hSv6LdC45hpmuPiFwjvaQe5cHsapvEXLj7vKYyOpt-T_UsdBr-sRRgh7JNPL8mzHkLCV8f3nPz8_OnHzZfq_uvt3c31fWWbWuRKMYudLjFq10DXY8eabj3gmLItcsGlQuZKbLC41ci2oFjNm7rXPbbAxTl5c-i7i9PDjCmbwSeLJcWI05yMUrIRjWQFlAfQximliL3ZRT9A3BvOzKra_FdtVo9Gl7uqNuuAi-OAuRvQnX4d3Zb662MdkoXQRxitTydM10JKvrb5eMCwyFg8RpNs8WvR-Yg2Gzf5Rxb5B86Engw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77543450</pqid></control><display><type>article</type><title>Automatic implantable cardioverter-defibrillator: Patient survival, battery longevity and shock delivery analysis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Gabry, Mark D. ; Brodman, Richard ; Johnston, Debra ; Frame, Rosemary ; Kim, Soo G. ; Waspe, Lawrence E. ; Fisher, John D. ; Furman, Seymour</creator><creatorcontrib>Gabry, Mark D. ; Brodman, Richard ; Johnston, Debra ; Frame, Rosemary ; Kim, Soo G. ; Waspe, Lawrence E. ; Fisher, John D. ; Furman, Seymour</creatorcontrib><description>The automatic implantable cardioverter-defibrillator (AICD) has been shown to reduce the mortality rate of patients with malignant ventricular tachyarrhythmias. This report describes experience with implantation of 36 automatic implantable cardioverter-defibrillators (AId-B and AID-BR models) in 22 persons over a 44 month patient follow-up period (mean 19.6 months). There were five deaths: two patients died suddenly 22 and 29 months, respectively, after their second implant, one died of congestive heart failure, one died of respiratory failure and one died of catheter sepsis. Although 11 (50%) of the 22 patients never received a countershock for a ventricular tachyarrhythmia and are still alive, the other 11 received one or more spontaneous countershocks. Nine patients (41%) experienced spurious shocks during the follow-up period. Assuming that the first shock for presumed ventricular tachyarrhythmia prevented death, the hypothetical cumulative survival of patients at 42 months would have been 34 ± 14.1% in the absence of an automatic implantable cardioverter defibrillator rather than the actual survival rate of 59 ± 16.8%. The cumulative device survival of the 36 AID-B units was 92 ± 5.62% at 15 months but diminished to 37 ± 14.4% by 20 months. No unit lasted longer than 22 months. There were 12 battery depletions. The number of shocks emitted did not influence unit longevity. The manufacturer's elective replacement indicator is of uncertain validity. Six units remained active 7 to 17 months after surpassing their replacement indicator. The automatic implantable cardioverter-defibrillator prolongs the life of many patients with otherwise intractable arrhythmias. Problems remain with this early generation device including the imprecision of its arrhythmia detection system resulting in false-positive discharges, the limited longevity of its battery, lack of programmability and an inadequate device follow-up system.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/S0735-1097(87)80477-1</identifier><identifier>PMID: 3584723</identifier><identifier>CODEN: JACCDI</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Electric Countershock - adverse effects ; Electric Countershock - instrumentation ; Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care ; Equipment Design ; Equipment Failure ; Female ; Humans ; Intensive care medicine ; Male ; Medical sciences ; Middle Aged ; Postoperative Complications ; Prostheses and Implants ; Tachycardia - mortality ; Tachycardia - therapy</subject><ispartof>Journal of the American College of Cardiology, 1987-06, Vol.9 (6), p.1349-1356</ispartof><rights>1987 American College of Cardiology Foundation</rights><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-70ceb85972d4abfeb04b4b4bad07c9e13157e0d047ace68e06a702142f8fe9a13</citedby><cites>FETCH-LOGICAL-c423t-70ceb85972d4abfeb04b4b4bad07c9e13157e0d047ace68e06a702142f8fe9a13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0735109787804771$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=8235511$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3584723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gabry, Mark D.</creatorcontrib><creatorcontrib>Brodman, Richard</creatorcontrib><creatorcontrib>Johnston, Debra</creatorcontrib><creatorcontrib>Frame, Rosemary</creatorcontrib><creatorcontrib>Kim, Soo G.</creatorcontrib><creatorcontrib>Waspe, Lawrence E.</creatorcontrib><creatorcontrib>Fisher, John D.</creatorcontrib><creatorcontrib>Furman, Seymour</creatorcontrib><title>Automatic implantable cardioverter-defibrillator: Patient survival, battery longevity and shock delivery analysis</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>The automatic implantable cardioverter-defibrillator (AICD) has been shown to reduce the mortality rate of patients with malignant ventricular tachyarrhythmias. This report describes experience with implantation of 36 automatic implantable cardioverter-defibrillators (AId-B and AID-BR models) in 22 persons over a 44 month patient follow-up period (mean 19.6 months). There were five deaths: two patients died suddenly 22 and 29 months, respectively, after their second implant, one died of congestive heart failure, one died of respiratory failure and one died of catheter sepsis. Although 11 (50%) of the 22 patients never received a countershock for a ventricular tachyarrhythmia and are still alive, the other 11 received one or more spontaneous countershocks. Nine patients (41%) experienced spurious shocks during the follow-up period. Assuming that the first shock for presumed ventricular tachyarrhythmia prevented death, the hypothetical cumulative survival of patients at 42 months would have been 34 ± 14.1% in the absence of an automatic implantable cardioverter defibrillator rather than the actual survival rate of 59 ± 16.8%. The cumulative device survival of the 36 AID-B units was 92 ± 5.62% at 15 months but diminished to 37 ± 14.4% by 20 months. No unit lasted longer than 22 months. There were 12 battery depletions. The number of shocks emitted did not influence unit longevity. The manufacturer's elective replacement indicator is of uncertain validity. Six units remained active 7 to 17 months after surpassing their replacement indicator. The automatic implantable cardioverter-defibrillator prolongs the life of many patients with otherwise intractable arrhythmias. Problems remain with this early generation device including the imprecision of its arrhythmia detection system resulting in false-positive discharges, the limited longevity of its battery, lack of programmability and an inadequate device follow-up system.</description><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Electric Countershock - adverse effects</subject><subject>Electric Countershock - instrumentation</subject><subject>Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care</subject><subject>Equipment Design</subject><subject>Equipment Failure</subject><subject>Female</subject><subject>Humans</subject><subject>Intensive care medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Postoperative Complications</subject><subject>Prostheses and Implants</subject><subject>Tachycardia - mortality</subject><subject>Tachycardia - therapy</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkFFrFDEQx4Mo9ax-hEIeRBTcmmw2l2xfpBSthYKC-hxmk1mNZnevSXbhvr1Z77jXkkAe5peZ-f8IueDskjO-_fCdKSErzlr1Vqt3mjVKVfwJ2XApdSVkq56SzQl5Tl6k9IcxttW8PSNnQupG1WJDHq7nPA2QvaV-2AUYM3QBqYXo_LRgzBgrh73vog8B8hSv6LdC45hpmuPiFwjvaQe5cHsapvEXLj7vKYyOpt-T_UsdBr-sRRgh7JNPL8mzHkLCV8f3nPz8_OnHzZfq_uvt3c31fWWbWuRKMYudLjFq10DXY8eabj3gmLItcsGlQuZKbLC41ci2oFjNm7rXPbbAxTl5c-i7i9PDjCmbwSeLJcWI05yMUrIRjWQFlAfQximliL3ZRT9A3BvOzKra_FdtVo9Gl7uqNuuAi-OAuRvQnX4d3Zb662MdkoXQRxitTydM10JKvrb5eMCwyFg8RpNs8WvR-Yg2Gzf5Rxb5B86Engw</recordid><startdate>19870601</startdate><enddate>19870601</enddate><creator>Gabry, Mark D.</creator><creator>Brodman, Richard</creator><creator>Johnston, Debra</creator><creator>Frame, Rosemary</creator><creator>Kim, Soo G.</creator><creator>Waspe, Lawrence E.</creator><creator>Fisher, John D.</creator><creator>Furman, Seymour</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19870601</creationdate><title>Automatic implantable cardioverter-defibrillator: Patient survival, battery longevity and shock delivery analysis</title><author>Gabry, Mark D. ; Brodman, Richard ; Johnston, Debra ; Frame, Rosemary ; Kim, Soo G. ; Waspe, Lawrence E. ; Fisher, John D. ; Furman, Seymour</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-70ceb85972d4abfeb04b4b4bad07c9e13157e0d047ace68e06a702142f8fe9a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Electric Countershock - adverse effects</topic><topic>Electric Countershock - instrumentation</topic><topic>Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care</topic><topic>Equipment Design</topic><topic>Equipment Failure</topic><topic>Female</topic><topic>Humans</topic><topic>Intensive care medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Postoperative Complications</topic><topic>Prostheses and Implants</topic><topic>Tachycardia - mortality</topic><topic>Tachycardia - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gabry, Mark D.</creatorcontrib><creatorcontrib>Brodman, Richard</creatorcontrib><creatorcontrib>Johnston, Debra</creatorcontrib><creatorcontrib>Frame, Rosemary</creatorcontrib><creatorcontrib>Kim, Soo G.</creatorcontrib><creatorcontrib>Waspe, Lawrence E.</creatorcontrib><creatorcontrib>Fisher, John D.</creatorcontrib><creatorcontrib>Furman, Seymour</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gabry, Mark D.</au><au>Brodman, Richard</au><au>Johnston, Debra</au><au>Frame, Rosemary</au><au>Kim, Soo G.</au><au>Waspe, Lawrence E.</au><au>Fisher, John D.</au><au>Furman, Seymour</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Automatic implantable cardioverter-defibrillator: Patient survival, battery longevity and shock delivery analysis</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>1987-06-01</date><risdate>1987</risdate><volume>9</volume><issue>6</issue><spage>1349</spage><epage>1356</epage><pages>1349-1356</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><coden>JACCDI</coden><abstract>The automatic implantable cardioverter-defibrillator (AICD) has been shown to reduce the mortality rate of patients with malignant ventricular tachyarrhythmias. This report describes experience with implantation of 36 automatic implantable cardioverter-defibrillators (AId-B and AID-BR models) in 22 persons over a 44 month patient follow-up period (mean 19.6 months). There were five deaths: two patients died suddenly 22 and 29 months, respectively, after their second implant, one died of congestive heart failure, one died of respiratory failure and one died of catheter sepsis. Although 11 (50%) of the 22 patients never received a countershock for a ventricular tachyarrhythmia and are still alive, the other 11 received one or more spontaneous countershocks. Nine patients (41%) experienced spurious shocks during the follow-up period. Assuming that the first shock for presumed ventricular tachyarrhythmia prevented death, the hypothetical cumulative survival of patients at 42 months would have been 34 ± 14.1% in the absence of an automatic implantable cardioverter defibrillator rather than the actual survival rate of 59 ± 16.8%. The cumulative device survival of the 36 AID-B units was 92 ± 5.62% at 15 months but diminished to 37 ± 14.4% by 20 months. No unit lasted longer than 22 months. There were 12 battery depletions. The number of shocks emitted did not influence unit longevity. The manufacturer's elective replacement indicator is of uncertain validity. Six units remained active 7 to 17 months after surpassing their replacement indicator. The automatic implantable cardioverter-defibrillator prolongs the life of many patients with otherwise intractable arrhythmias. Problems remain with this early generation device including the imprecision of its arrhythmia detection system resulting in false-positive discharges, the limited longevity of its battery, lack of programmability and an inadequate device follow-up system.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>3584723</pmid><doi>10.1016/S0735-1097(87)80477-1</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0735-1097
ispartof Journal of the American College of Cardiology, 1987-06, Vol.9 (6), p.1349-1356
issn 0735-1097
1558-3597
language eng
recordid cdi_proquest_miscellaneous_77543450
source MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adult
Aged
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Electric Countershock - adverse effects
Electric Countershock - instrumentation
Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care
Equipment Design
Equipment Failure
Female
Humans
Intensive care medicine
Male
Medical sciences
Middle Aged
Postoperative Complications
Prostheses and Implants
Tachycardia - mortality
Tachycardia - therapy
title Automatic implantable cardioverter-defibrillator: Patient survival, battery longevity and shock delivery analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T02%3A21%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Automatic%20implantable%20cardioverter-defibrillator:%20Patient%20survival,%20battery%20longevity%20and%20shock%20delivery%20analysis&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Gabry,%20Mark%20D.&rft.date=1987-06-01&rft.volume=9&rft.issue=6&rft.spage=1349&rft.epage=1356&rft.pages=1349-1356&rft.issn=0735-1097&rft.eissn=1558-3597&rft.coden=JACCDI&rft_id=info:doi/10.1016/S0735-1097(87)80477-1&rft_dat=%3Cproquest_cross%3E77543450%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77543450&rft_id=info:pmid/3584723&rft_els_id=S0735109787804771&rfr_iscdi=true